Skip to main content
TipRanks
Go Ultimate75% OFF

Amneal Pharmaceuticals (2DT) Stock Statistics & Valuation Metrics

2 Followers

Total Valuation

Amneal Pharmaceuticals has a market cap or net worth of EUR 6.80B. The enterprise value is EUR 9.98B.

Market Cap
EUR 6.80B
Enterprise Value
EUR 9.98B

Share Statistics

Amneal Pharmaceuticals has 348,412,720 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
348,412,720
Owned by Insiders
36.76%
Owned by Institutions
46.50%

Financial Efficiency

Amneal Pharmaceuticals’s return on equity (ROE) is -1.02 and return on invested capital (ROIC) is 13.80%.

Return on Equity (ROE)
-1.02
Return on Assets (ROA)
0.02
Return on Invested Capital (ROIC)
13.80%
Return on Capital Employed (ROCE)
0.15
Revenue Per Employee
346.98K
Profits Per Employee
8,282.414
Employee Count
8,700
Asset Turnover
0.82
Inventory Turnover
3.11

Valuation Ratios

The current PE Ratio of Amneal Pharmaceuticals is 49.74. Amneal Pharmaceuticals’s PEG ratio is 0.02.

PE Ratio
49.74
PS Ratio
2.33
PB Ratio
13.52
Price to FCF
184.45
Price to Operating Cash Flow
39.33
PEG Ratio
0.02

Income Statement

In the last 12 months, Amneal Pharmaceuticals had revenue of 3.02B and earned 72.06M in profits. Earnings per share was 0.23.

Revenue
3.02B
Gross Profit
1.14B
Operating Income
423.09M
Pretax Income
139.21M
Net Income
72.06M
EBITDA
603.87M
Earnings Per Share (EPS)
0.23

Cash Flow

In the last 12 months, operating cash flow was 182.61M and capital expenditures -142.20M, giving a free cash flow of 40.41M billion.

Operating Cash Flow
182.61M
Free Cash Flow
40.41M
Free Cash Flow per Share
0.12

Dividends & Yields

Amneal Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
0.54%
Earnings Yield
2.06%

Stock Price Statistics

Beta
0.71
52-Week Price Change
96.94%
50-Day Moving Average
17.16
200-Day Moving Average
13.66
Relative Strength Index (RSI)
63.84
Average Volume (3m)
101

Important Dates

Amneal Pharmaceuticals upcoming earnings date is Feb 26, 2027, TBA (Not Confirmed).

Last Earnings Date
Nov 03, 2026
Next Earnings Date
Feb 26, 2027
Ex-Dividend Date
―

Financial Position

Amneal Pharmaceuticals as a current ratio of 2.17, with Debt / Equity ratio of -3865.40%

Current Ratio
2.17
Quick Ratio
1.48
Debt to Market Cap
0.67
Net Debt to EBITDA
4.02
Interest Coverage Ratio
1.75

Taxes

In the past 12 months, Amneal Pharmaceuticals has paid 11.28M in taxes.

Income Tax
11.28M
Effective Tax Rate
0.08

Enterprise Valuation

Amneal Pharmaceuticals EV to EBITDA ratio is 15.82, with an EV/FCF ratio of 261.46.

EV to Sales
3.31
EV to EBITDA
15.82
EV to Free Cash Flow
261.46
EV to Operating Cash Flow
57.85

Balance Sheet

Amneal Pharmaceuticals has EUR 157.40M in cash and marketable securities with EUR 3.28B in debt, giving a net cash position of -EUR 3.13B billion.

Cash & Marketable Securities
EUR 157.40M
Total Debt
EUR 3.28B
Net Cash
-EUR 3.13B
Net Cash Per Share
-EUR 8.97
Tangible Book Value Per Share
-EUR 5.01

Margins

Gross margin is 40.24%, with operating margin of 15.61%, and net profit margin of 4.62%.

Gross Margin
40.24%
Operating Margin
15.61%
Pretax Margin
6.93%
Net Profit Margin
4.62%
EBITDA Margin
20.90%
EBIT Margin
14.84%

Analyst Forecast

The average price target for Amneal Pharmaceuticals is EUR 22.53, which is 11.43% higher than the current price. The consensus rating is Strong Buy

Price Target
EUR 22.53
Price Target Upside
16.72% Upside
Analyst Consensus
Strong Buy
Analyst Count
6
Revenue Growth Forecast
3.60%
EPS Growth Forecast
2761.42%

Scores

Smart Score
10
AI Score
―